The MATCH (Medication Aids for Tobacco Cessation and Health) Study (MATCH)
Evaluating the Real-world Effectiveness of Varenicline and Bupropion for Long-term Smoking Cessation
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5T 1P7
- Centre for Addiction and Mental Health, Nicotine Dependence Clinic
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- At least 19 years of age
- Smoking at least 10 cigarettes per day
- Smoked daily for at least the past year
- Have an intention of quit smoking in the next 30 days.
Exclusion Criteria:
- History of psychotic disorder or eating disorder
- Brain injury
- Seizure disorder
- Pregnancy, lactation, or at risk of becoming pregnant
- Allergy or sensitivity to bupropion or varenicline
- Taking monoamine oxidase inhibitors (anti-depressants), thioridazine or Wellbutrin or other medication containing bupropion hydrochloride.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Bupropion
Bupropion hydrochloride SR, Sandoz Canada, Boucherville, Quebec.
Dispense for 12 weeks.
One tablet (150mg) once daily for first three days, then twice daily for the remainder of 12 weeks.
|
The e-mails will include tips on several things other than the medications that participants can do to help them quit smoking.
The contents of the emails will vary from week to week.
The e-mails will provide tips on ways to create an atmosphere that promotes quitting and staying abstinence.
They will also include recommendations on how to address issues with withdrawal symptoms and cravings.
In addition, they will provide positive motivational messages by stating facts on benefits of quitting smoking.
|
|
Experimental: Varenicline
Varenicline tartrate (Champix®), Pfizer Canada Inc., Kirkland, Quebec.
Dispense for 12 weeks.
One tablet (0.5mg) once daily for first three days, then one tablet (0.5 mg) twice daily for next four days, then 1 mg (one 1mg tablet or two 0.5mg tablets) twice daily for the remainder of 12 weeks.
|
The e-mails will include tips on several things other than the medications that participants can do to help them quit smoking.
The contents of the emails will vary from week to week.
The e-mails will provide tips on ways to create an atmosphere that promotes quitting and staying abstinence.
They will also include recommendations on how to address issues with withdrawal symptoms and cravings.
In addition, they will provide positive motivational messages by stating facts on benefits of quitting smoking.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in smoking status over time
Time Frame: At 12, 26, and 52 weeks following start of treatment
|
Related to effectiveness of smoking cessation intervention, The 7-day point prevalence abstinent rate is defined as not having smoked, even a puff, over the previous seven days.
|
At 12, 26, and 52 weeks following start of treatment
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pre-post Decisional Balance Scores
Time Frame: upon first patient enrolled and 1 month following last patient enrolled
|
Related to physician practice changes after being approached by their patients about smoking cessation medications and being informed about the study.
|
upon first patient enrolled and 1 month following last patient enrolled
|
|
Continuous Abstinence
Time Frame: 12, 26 and 52 weeks after start of treatment
|
A measure of long-term smoking cessation and time to relapse.
|
12, 26 and 52 weeks after start of treatment
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Genetic Polymorphisms
Time Frame: About 5 weeks following participants' enrollment
|
Polymorphisms in genes involved in treatment medication and nicotine's metabolism and receptors, as well as genetic variations involved in dopamine neurotransmitter pathway are investigated.
DNA analysis is performed using mailed-in saliva samples.
|
About 5 weeks following participants' enrollment
|
|
Personality Traits
Time Frame: At baseline
|
The ten aspects of personality traits (2 aspects for each big five domains of personality), as described by BFAS (Big Five Aspect Scales), are measured.
|
At baseline
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
General Publications
- Zhang H, Mansoursadeghi-Gilan T, Hussain S, Veldhuizen S, Le Foll B, Selby P, Zawertailo L. Evaluating the effectiveness of bupropion and varenicline for smoking cessation using an internet-based delivery system: A pragmatic randomized controlled trial (MATCH study). Drug Alcohol Depend. 2022 Mar 1;232:109312. doi: 10.1016/j.drugalcdep.2022.109312. Epub 2022 Feb 9.
- Zawertailo L, Mansoursadeghi-Gilan T, Zhang H, Hussain S, Le Foll B, Selby P. Varenicline and Bupropion for Long-Term Smoking Cessation (the MATCH Study): Protocol for a Real-World, Pragmatic, Randomized Controlled Trial. JMIR Res Protoc. 2018 Oct 18;7(10):e10826. doi: 10.2196/10826.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Chemically-Induced Disorders
- Substance-Related Disorders
- Tobacco Use Disorder
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Cholinergic Agents
- Enzyme Inhibitors
- Psychotropic Drugs
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Antidepressive Agents
- Dopamine Agents
- Cytochrome P-450 Enzyme Inhibitors
- Nicotinic Agonists
- Cholinergic Agonists
- Antidepressive Agents, Second-Generation
- Cytochrome P-450 CYP2D6 Inhibitors
- Dopamine Uptake Inhibitors
- Bupropion
- Varenicline
Other Study ID Numbers
Other Study ID Numbers
- 200/2012
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.